Daar is 'n jongste deurbraak in nie-kleinselle longkanker. N tipe van immunisering wat nie-kleinselle longkanker (NSCLC) kan behandel, het fase 3 kliniese goedkeuring ervaar en het 'n groot terapeutiese impak op nie-kleinselle longsiekte. Dit is tans toeganklik in baie min lande.
As an anti-idiotype monoclonal antibody, the vaccine enables lung cancer patients to respond strongly to specific glycosylated gangliosides (NeuGcGM3) in cancer cells. Compared with the best supportive care, lung entstof teen kanker can improve the survival rate of patients with relapsed stage and advanced (stage IIIB / IV) NSCLC.
Rather than numerous warm blooded creatures, including gorillas, we can’t recognize the nearness of NeuGcGM3 gangliosides in typical human tissues and liquids. Be that as it may, NeuGcGM3 gangliosides are profoundly communicated in certain human malignant growth cells. In non-little cell lung malignancy tests, gangliosides were identified in over 90% of non-little cell lung tumors. Thusly, NeuGcGM3 ganglioside can be utilized as a ground-breaking objective for lung malignant growth antibodies.
Nadat die onvatbare raamwerk eksplisiete teenliggaampies teen 'n antigeen, kan dit teenliggaampies skep teen die uniekheid van die hoofantigeen, wat die weerstandbiedende raamwerk van binne kan beheer. In die nasleep van geïmmuniseer teen hierdie long kwaadaardige groei immunisering, it can advance the generation of antibodies against this antigen, assigned Ab1. These Ab1 antibodies are fit for delivering a progression of hostile to idiotypic antibodies, assigned Ab2. The idiotypes of these exceptional antibodies are fused into the antigen-restricting site of Ab1, with the goal that these extraordinary antibodies produce a particular resistant reaction to regular antigens. Hence, vaccination with Ab2 immunizer can advance the creation of Ab3 (hostile to against idiotype neutralizer), and this Ab3 counter acting agent can perceive the first antigen perceived by Ab1. Some Ab2 antibodies of this sort invigorate the safe framework to actuate defensive resistance against tumor antigene.
Dit is klinies gedemonstreer dat die longsiekte immunisering word baie verduur en het beter welstanduitvoering. Talle basiese simptome kom net plaaslik voor (infusieplek) en is oor die algemeen sag en van kort lengte. Ongeag of die teenliggaam aan pasiënte gegee word nadat hul toestand gedisintegreer het, hul algemene uithouvermoë het verbeter.
Tans word hierdie soort longkwaadgroei-immunisering nie in Indië bevorder nie.
